Actively Recruiting
Phase 1 Study of BHV-1400 Delivered by Injection for Treating Adults with Biopsy-Confirmed IgA Nephropathy
Led by Biohaven Therapeutics Ltd. · Updated on 2026-06-23
20
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and tolerability of BHV-1400 as a treatment for people with IgA Nephropathy, a kidney condition confirmed by biopsy. This Phase 1 study aims to observe how participants respond to BHV-1400, an investigational drug administered under medical supervision. Participants will receive BHV-1400 through subcutaneous injections. This open-label study involves a single group receiving the study drug without a placebo comparison. The treatment period and dosing schedule are designed to monitor safety outcomes over a year. During the study, participants will be closely monitored for serious adverse events, adverse events leading to discontinuation, and deaths, along with laboratory abnormalities of grade 3 or 4 severity. The study lasts up to one year and includes regular evaluations to ensure participant safety and gather detailed safety data.
CONDITIONS
Brief Title
Study of BHV-1400 in IgA Nephropathy
Research Team
C
Chief Medical Officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
